OS Therapies Inc (OSTX): Utang-utang marang kapitalisasi buku

Logo grafis OS Therapies Inc. (OSTX)

OS Therapies Incorporated relies on a compact staff of scientists, outsourcing its research to external contractors. Efficient logistics for biologics ensure stable margins and supply reliability. The ratio of debt capital to the company's book capitalization on the GURU.Markets dynamic chart reflects a trend where the value of 0.00 serves as the baseline indicator. However, in the rare oncology niche, large pharma behemoths pose a serious threat, as they are capable of limiting the monopoly profits of small businesses.

OS Therapies Incorporated (OSTX) - Utang-utang marang nilai buku saka 02.08.2024 nganti 28.10.2026
Barang utama OS Therapies Inc.

This ratio determines the degree of the business's dependence on borrowed funds relative to its equity. Analyzing total debt against book capitalization allows for an assessment of financial stability and leverage levels. The metric is calculated as the ratio of all liabilities to the value of net assets. A decrease in this value confirms the autonomy of OS Therapies Incorporated (OSTX). The diversification of clinical trials minimizes risks, supporting capital stability during the development of targeted therapy.

Karo sapa OS Therapies Incorporated saingan

ONC - Rasio utang marang kapitalisasi buku|Rasio utang marang nilai buku halozyme.com HALO|RVMD: Utang-utang marang kapitalisasi buku|AAPG - Utang marang nilai buku|Utang-utang marang kapitalisasi buku CGON|URGN (UroGen Pharma Corp) - Utang-utang marang nilai buku|BCAX - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik personalis.com (PSNL)|Erasca (ERAS) - Utang marang nilai buku|Rasio utang marang aset resik Delcath Systems Inc (DCTH)|YmAbs - Utang-utang marang kapitalisasi buku|AURA - Utang marang nilai buku|Candel - Utang marang nilai buku|ARAY: Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku sellaslifesciences.com SLS|Actuate Therapeutics Inc. (ACTU) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku CTOR (Citius Oncology, Inc)|Utang-utang marang nilai buku HURA|Protara Therapeutics - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku FATE (fatetherapeutics.com)|Rasio utang marang kapitalisasi buku WHWK|TCRX - Utang-utang marang aset resik|Utang marang nilai buku Champions Oncology Corp (CSBR)|XBiotech Inc. (XBIT) - Rasio utang marang aset resik|CVM - Utang marang nilai buku|radiopharmtheranostics.com (RADX) - Utang marang modal buku|ARTV - Utang-utang marang kapitalisasi buku|Rasio utang marang aset resik Adlai Nortye Limited|Veru Pharma - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku TPST (Tempest Therapeutics Corp)|Rasio utang marang kapitalisasi buku Xilio Therapeutics|Rasio utang marang aset resik Renovaro Biosciences RENB|Mural Bio - Utang-utang marang kapitalisasi buku|KAPA: Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku onkuretherapeutics.com (OKUR)|CytoMed Therapeutics Limited (GDTC) - Rasio utang-utang marang kapitalisasi buku|CRIS: Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik Apollomics Corp|Tharimmune - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku ADVB (advanbiomed.com)|Rasio utang marang kapitalisasi buku GNPX|CLDI - Utang-utang marang aset resik|Utang marang nilai buku Sunshine Biopharma, Inc. (SBFM)|XBIO - Rasio utang marang aset resik|Salarius Pharmaceuticals, Inc. - Utang-utang marang kapitalisasi buku|PPBT (Purple Biotech Ltd) - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku American Oncology Network Inc (AONC)|Rasio utang marang nilai buku BeiGene Ltd|Utang-utang marang kapitalisasi buku CKPT (Checkpoint Therapeutics)|Utang marang nilai buku ELEV (elevationoncology.com)|ICAD: Rasio utang marang kapitalisasi buku|Ikena Oncology Inc. - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku Notable Labs Inc. (NTBL)|VIRX: Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku MorphoSys AG (MOR)|NAYA (nayabiosciences.com) - Rasio utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku AAPGV (Ascentage Pharma)